抗菌薬の世界市場:セファロスポリン、ペニシリン、フルオロキノロン、マクロライド系薬、カルバペネム系薬...市場調査レポートについてご紹介

【英文タイトル】Antibacterial Drugs: World Industry and Market Prospects 2016-2026

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

1. Report Overview
1.1 Overview of Findings
1.2 Why You Should Read This Report
1.3 How This Report Delivers
1.4 Main Questions Answered by This Analysis
1.5 Who is This Study For?
1.6 Research and Analysis Methods
1.7 Frequently Asked Questions (FAQs)
1.8 Some Associated Reports

2. Introduction to Antibacterial Drugs
2.1 Types of Bacterial Infection
2.2 Main Bacteria Causing Infections in Human Beings
2.3 Incidence and Mortality Profiles for Common Bacterial Infection
2.4 Treating Infections
2.4.1 The History of Antibacterial Drug Development
2.4.2 Mechanisms of Action
2.4.3 Leading Classes of Antibacterial Medicines
2.4.3.1 Cephalosporins
2.4.3.2 Penicillins
2.4.3.3 Carbapenems
2.4.3.4 Fluoroquinolones
2.4.3.5 Macrolides
2.4.4 Antibacterial Drug Resistance

3. Antibacterial Drugs: World Market, 2016-2026
3.1 Antibacterials’ Revenues Plateau between 2010 and 2015
3.2 Antibacterial Agents – Market Segmentation
3.3 Antibiotics Market Forecast, 2016-2026: Decline in Revenues for Fluoroquinolones
3.4 Drivers and Restraints in the Antibacterials Market, 2016-2026
3.5 Generic Erosion and Prescription Control will Limit Market Growth
3.6 Changes in that Industry Sector’s Market Shares, 2016-2026
3.7 Pfizer is the Leader in the Antibacterial Drugs Market, 2014
3.8 Fragmented Market to Fracture Further

4. Cephalosporins Market Forecast, 2016-2026
4.1 Cephalosporins Market 2015 – No Dominant Brands
4.1.1 Late-Stage Cephalosporins to Gain Market Share Between 2016 and 2026
4.1.2 Basilea, Merck, Actavis and AstraZeneca to Lead Cephalosporin Market Between 2016 and 2026
4.1.3 Drivers and Restraints on the Cephalosporins Market, 2016-2026
4.1.4 Cephalosporins Lack Market Exclusivity
4.1.5 Strong Pipeline for Novel Cephalosporins
4.1.6 Rocephin (Roche) – The Only Treatment for Gonorrhoea in the US
4.1.6.1 Off Patent but Still Effective
4.1.6.2 Declining Revenues Owing to Competition – Forecast 2016-2026
4.1.7 Sulperazon – India’s Leading Treatment for RTIs and UTIs
4.1.7.1 Continued Growth in the Emerging Markets, Revenue Forecast 2016-2026
4.1.8 Zinnat/Ceftin – GSK’s Established Cephalosporin
4.1.8.1 Continued Decline in Revenue – Forecast 2016-2026
4.1.9 Meiact – A Broad Range Community Antibiotic
4.1.9.1 Spectracef Sales in the US Leads to Pass the Product
4.1.9.2 Competition in Japan to Hinder Growth – Revenue Forecast 2016-2026
4.1.10 Flomox – Shionogi’s Third-Generation Cephalosporin
4.1.10.1 Patent Issues and Litigation
4.1.10.2 Genericisation and Safety to Restrict Sales – Forecast 2016-2026
4.1.11 Zinforo/Teflaro (Ceftaroline Fosamil): The First of the Fifth- Generation Cephalosporins
4.1.11.1 Unmet Needs in Pneumonia to Drive Growth – Revenue Forecast 2016-2026
4.1.12 Zeftera (ceftobiprole): Approved for Pneumonia in Europe
4.1.12.1 Future Sales Dictated by US Approval – Revenue Forecast 2016-2026
4.1.13 CXA-201 (Ceftolozane-Tazobactam): The Next Blockbuster Antibacterial
4.1.13.1 Broad Label and Spectrum of Activity Leads to Rapid Uptake – Revenue Forecast 2016-2026
4.1.14 CAZ-AVI (Ceftazidime-Avibactam): Approved in 2015
4.1.14.1 Competition from CXA-201 to Limit Sales – Forecast 2016-2026

5. Penicillins Market Forecast, 2016-2026
5.1 Generics and Augmentin Dominate the Penicillins Market in 2015
5.2 Augmentin to Lose its Dominance over the Coming 10 Years – Market Shares for Penicillin Drugs, 2016-2026
5.3 Penicillin Antibacterials: Market Forecast 2016-2026
5.4 Drivers and Restraints for the Penicillin Market 2016-2026
5.5 Augmentin – Blockbuster Facing Generic Competition
5.5.1 Augmentin – Challenges in Some Countries
5.5.2 Stable Revenues in Spite of Generic Competition
5.5.3 Revenue Forecast 2016-2026
5.6 Zosyn/Tazocin (Piperacillin-Tazobactam) – Pneumonia Therapeutic
5.6.1 Patent Expiry and Revenue Extension for Pfizer
5.6.2 Historic and Current Revenue Performance
5.6.3 Revenue Forecast 2016-2026
5.7 Unasyn – Gram-negative and Positive Antibiotic
5.7.1 Falling Revenues – Forecast 2016-2026
5.8 Amoxil (Amoxicillin) – A Historic Antibacterial Brand
5.8.1 Marginal Decline in Revenue – Forecast 2016-2026
5.9 Generic Amoxicillin
5.9.1 Revenue Forecast 2016-2026
5.10 Generic Amoxicillin-Clavulanic Acid
5.10.1 Revenue Forecast 2016-2026

6. Fluoroquinolone Market Forecast, 2016-2026
6.1 The Fluoroquinolone Market 2015
6.2 Changing Market Share for Fluoroquinolone Antibacterials, 2016-2026
6.3 Fluoroquinolone Antibacterial Drugs: Market Forecast 2016-2026
6.4 Trends in the Fluoroquinolone Market
6.4.1 Safety Fears for Fluoroquinolones
6.4.2 Avelox Patent Cliff
6.4.3 Inhaled Fluoroquinolone Formulations
6.5 Fluoroquinolone Market Forecast 2016-2026
6.6 Avelox
6.6.1 Safety Profile Hampers Sales
6.6.2 Generic Competition
6.6.3 Revenue Forecast 2016-2026
6.7 Cravit and Levaquin
6.7.1 Generic Competition Affecting Revenue Worldwide
6.7.2 Lifecycle Management for Cravit and Levaquin
6.7.3 Revenue Forecast 2016-2026
6.8 Vigamox
6.8.1 Branded and Generic Challenges 2010-2013
6.8.2 Moxeza: A Next-Generation Form of Vigamox
6.8.3 Revenue Forecast 2016-2026
6.9 Cirpodex and Cipro – Two Preparations of Ciprofloxacin
6.9.1 Ciprodex: A Second-Generation Ophthalmic Antibiotic
6.9.1.1 Revenue Forecast 2016-2026
6.9.2 Cipro Revenue Forecast 2016-2026: Continued Generic Erosion
6.10 Geninax
6.10.1 Revenue Forecast 2016-2026
6.11 Delafloxacin
6.11.1 Revenue Forecast 2016-2026

7. Macrolide Market Forecast, 2016-2026
7.1 Macrolide Market in 2015
7.2 Changing Market Share for Macrolides, 2016-2026
7.3 Macrolide Antibacterials: Market Forecast 2016-2026
7.4 Trends in the Macrolide Market
7.5 Biaxin/Clarith
7.5.1 Past Revenue 2011-2014
7.5.2 Lifecycle Management for Continued Market Presence
7.5.3 Revenue Forecast 2016-2026
7.6 Zithromax
7.6.1 Concerns Over Safety and Marketing in the US
7.6.2 Effectiveness in Drug-Resistant Strains
7.6.3 Revenue Forecast 2016-2026
7.7 Dalacin
7.7.1 Revenue Forecast 2016-2026
7.8 Dificid
7.8.1 Rapid Uptake Slowed by High Cost
7.8.2 New Approvals and Expanded Indications
7.8.3 Revenue Forecast 2016-2026
7.9 Solithromycin
7.9.1 Revenue Forecast 2016-2026

8. Carbapenem Market Forecast, 2016-2026
8.1 Carbapenem Market 2015
8.2 Changing Market Share for Carbapenems, 2016-2026
8.3 Carbapenem Market Forecast, 2016-2026
8.4 Trends in the Carbapenem Market
8.4.1 Rising Prevalence of Carbapenemases and β-Lactamases
8.4.2 No New Carbapenems in Late-Stage Trials
8.5 Merrem/Meropenem
8.5.1 Generics Affecting Revenue Worldwide
8.5.2 Revenue Forecast 2016-2026
8.6 Primaxin
8.6.1 Combination Therapy for Lifecycle Management
8.6.2 Historic and Current Revenues
8.6.3 Revenue Forecast 2016-2026
8.7 Invanz
8.7.1 Revenue Forecast 2016-2026
8.8 Doribax
8.8.1 Doribax in HAP and VAP
8.8.2 Lifecycle Management in Japan and the Rest of the World
8.8.3 Revenue Forecast 2016-2026

9. Other Antibiotic Drugs Forecast, 2016-2026
9.1 The Market for Other Classes of Antibacterial Drugs
9.2 Changing Market Share for Fluoroquinolone Antibacterials 2016-2026
9.3 Other Antibacterials: Market Forecast, 2016-2026
9.4 Trends in the Other Classes of Antibacterial Drugs
9.4.1 New Oxazolidinones Will Drive Growth
9.4.2 New Drug Classes to Drive Submarket Growth to 2026
9.5 Zyvox – The Market Leading Antibacterial
9.5.1 MRSA Activity Driving Revenue Growth
9.5.2 Promise in Tuberculosis and Anthrax
9.5.3 Patents, Litigation, and Competition – When and Who Will Produce Generic Linezolid?
9.5.4 Flat Growth to Patent Expiry, Revenue Forecast 2016-2026
9.6 Cubicin – The Leading Brand for ABSSSIs
9.6.1 Revenue Boosted by Approvals Worldwide
9.6.2 Patents, Litigation and Deals – How Long Will Market Exclusivity Last?
9.6.3 Sustained Growth through to 2020, Revenue Forecast 2016-2026
9.7 Tygacil – A Tetracycline With Many Approved Indications
9.7.1 Concerns Limiting Revenue Potential
9.7.2 Competition from Other Therapies Restricts Growth: Revenue Forecast 2016-2026
9.8 TOBI/TOBI Podhaler – The Market Leading Inhaler for Cystic Fibrosis
9.8.1 Historic and Current Revenue Performance
9.8.2 Approvals and Launches in New Markets to Drive Revenue Growth
9.8.3 Competition to Limit Long-term Growth, Revenue Forecast 2016-2026
9.9 Solodyn – A Treatment for Severe Acne
9.9.1 Generic Competition and Lifecycle Management
9.9.2 Limited Potential for Dermatology, Revenue Forecast 2016-2026
9.10 Vibativ – Limited Potential for Novel Lipoglycopeptide
9.10.1 Astellas Ends its Collaboration with Theravance
9.10.2 Limited HAP Label in the US – Revenue Forecast 2016-2026
9.11 Sirturo – A New Option for Multi-Drug Resistant TB
9.11.1 Chronic Treatment Schedule and Emerging Demand Drive Revenue Growth, Forecast 2016-2026
9.12 Tedizolid – Market Leading Follow-on to Zyvox?
9.12.1 Competition Increasing: Revenue Forecast 2016-2026
9.13 Oritavancin – An Antibiotic With a Novel PK Profile
9.13.1 Single Dose Differentiation to Deliver Market Share (%), Revenue Forecast 2016-2026
9.14 Dalbavancin – Competing in a Crowded Indication
9.14.1 Sustained Growth Over the Coming 10 Years, Revenue Forecast 2016-2026
9.15 Surotomycin –Treatment for C. difficile
9.15.1 Delayed Launch to Limit Potential, Revenue Forecast 2016-2026
9.16 Nemonoxacin – Taiwan’s Global Antibacterial Drug
9.16.1 Slow Initial Growth to Accelerate with US Approval, Revenue Forecast 2016-2026

10. The Leading National Markets, 2016-2026
10.1 US and China Dominate the Global Antibacterial Market, But For Different Reasons
10.2 Above-Average Growth in US: Regional Forecasts, 2016-2026
10.3 China to Slump in Market Share, While Brazil and India Push on
10.4 Incidence of Infection by Country, 2015
10.4.1 Incidence of Pneumonia in National Markets – Pneumonia Predominant in America
10.4.2 Incidence of Community Acquired Urinary Tract Infections in National Markets – High Incidence Rates in the UK, US and Spain
10.4.3 Incidence of Bacterial Skin and Skin Structure Infections in National Markets – High Potential in the US
10.4.4 Incidence of Upper Respiratory Tract Infections in National Markets – Europe Leads the Way
10.5 Antibacterial Drug Consumption by Country, 2015
10.5.1 Antibacterial Drug Consumption in the Major National Markets
10.5.2 Antibacterial Drug Consumption in Some Other National Markets
10.6 The Antibacterials Market in the US
10.6.1 Continued Dominance of the US Market
10.7 The European Union Forms Second Largest Regional Market
10.7.1 Marginal Expansion in Antibacterial Spending – Market Forecast 2016-2026
10.7.2 Action to Encourage Antibacterial Drug Development in the EU
10.7.3 Italy Continues to Lead the Way in Antibiotic Use
10.7.4 The French Fascination with Expensive Antibacterial Drugs
10.7.5 Germany – Europe’s Antibiotic Steward
10.7.6 Rising Use of Antibacterials Drugs in the UK
10.7.7 Spanish Antibacterials Market to Expand from 2020 to 2026
10.8 Japan – Still the Fourth Largest National Market
10.8.1 The Pause Before Growth in the Japanese Market
10.9 Will South Korea Continue Its High Use of Antibiotics?
10.10 BRIC Nation Sales Still Expanding – Market Forecast 2016-2026
10.11 Chinese Antibacterial Market Bloated by Reported Overuse
10.11.1 Developing Antibacterials in China, for China
10.11.2 Governmental Controls Subdue Recent Growth – Market Forecast 2016-2026
10.12 Indian Market to Expand by 50% Over the Forecast Period
10.12.1 Restricting Antibiotic Use in India
10.12.2 Sustained Expansion of the Indian Market, Forecast 2016-2026
10.13 Brazilian Antibacterial Market to Double in Size
10.13.1 Brazilian Market to Be Driven by Drug Resistance
10.14 Russia: TB Prevalence to Stimulate Antibiotic Sales – Forecast 2016-2026

11. Antibacterials R&D Pipeline Review, 2016
11.1 Gram-Positive vs. Gram-Negative
11.2 Pipeline Dominated by Small Molecule Drugs
11.3 Leading Phase III Pipeline Treatment Candidates
11.3.1 Surotomycin – Broad C. difficile Treatment to Reduce Relapse
11.3.2 Tedizolid – More Potent Than Zyvox with Fewer Doses?
11.3.3 Delafloxacin – A Leading pH Activated, Broad Spectrum Fluoroquinolone
11.3.4 Solithromycin – Fluroketolide with Favourable Side Effect Profile
11.3.5 Eravacycline – Treating Gram-Negative cUTIs and cIAIs
11.3.6 Plazomicin – Straight to PIII in Carbapenem Resistant Infections
11.3.7 Cadazolid: Largest PIII C. Difficile Trial
11.3.8 Omadacycline – Another Phase III-Ready Partnership
11.3.9 Relebactam – A Novel β-Lactamase Combination
11.3.10 CEM-102 (Fusidic acid) – Cempra’s Second Pipeline Candidate
11.3.11 BC-3781- Unique Mechanism of Action at 23S?
11.4 Leading Phase II Antibacterial Drug Candidates
11.4.1 AZD5847: An Oxazolidinone for TB
11.4.2 Radezolid – Apparently on Melinta’s Back-Burner for Now
11.4.3 AFN-1252: Highly Specific S. Aureus Antibacterial
11.4.4 TD-1792 – A Russian Antibacterial Medicine
11.4.5 Brilacidin – A Novel Peptide Antibacterial Agent
11.4.6POL7080 – Polyphor and Roche in Multi-Million Dollar Deal
11.5 Inhaled Antibiotics – Advantages in Lung Infections
11.5.1 Cayston: Competition for Novartis?
11.5.2 ARIKACE – Targeting P. aeruginosa
11.5.3 Aeroquin – Better than Podhaler?
11.5.4 BAYQ3939 – Developments for Cystic Fibrosis
11.5.5 NKTR-061: Targeting Intubated Pneumonia
11.5.6 Pulmaquin: A Second Ciprofloxacin Candidate
11.5.7 AeroVanc Targets MRSA Infections
11.5.8 Inhaled Amikacin-Fosfomycin – Adjunctive Therapy for VAP
11.6 Biologics – Truly Novel Antibacterial Therapeutics
11.6.1 MK-3415A: First Antibacterial mAb to the Market?
11.6.2 KB001A – The Leading Antibody Against P. aeruginosa
11.6.3 Aridis Pharmaceuticals: Targeting P. aeruginosa and S. aureus
11.6.4 MEDI4893 – Early Stage mAb to S. Aureus
11.7 Other Classes
11.7.1 AZD0914 – Novel DNA Gyrase Inhibitor
11.7.2 MRX-I – Safer Oral Oxazolidinone to Treat MRSA
11.7.3 GSK2140944 – BTI Class of Antibiotics
11.7.4 Carbavance – to Treat CRE

12. Qualitative Analysis of the Antibacterials Industry and Market, 2016
12.1 SWOT Analysis: Strengths, Weaknesses, Opportunities and Threats Affecting Antibacterials, their Developers, Producers and Marketers
12.2 STEP Analysis: Social, Technological, Economic and Political Forces Affecting the Antibacterial Drug Industry and Market
12.2.1 Social Factors
12.2.2 Technological Developments
12.2.3 Economic Pressures
12.2.4 Political Issues
12.3 Market is Well Established and Demand Will Remain Strong
12.4 High Prevalence of Bacterial Infection Worldwide
12.5 Worldwide Demand for Antibacterials
12.6 Animal Models of Infection are Highly Predictive Compared with Other Therapeutic Fields
12.7 Cutting into a Saturated Market
12.8 Superior Benefit over Generics?
12.9 Resistance – Nature’s Patent Expiry
12.10 Acute Treatment Limits Commercial Potential
12.11 Did Big Pharma Back Away from Antibacterial Drugs?
12.12 Resistance Will Continue to Present New Targets
12.13 First Biologic Antibacterials
12.14 Potential for Smaller Firms to Capitalise
12.15 Developing Preventative Vaccines Rather Than Treatments
12.16 Antibacterial Stewardship Reduces Usage
12.17 Clinical Confusion from Inconsistent Guidance Between Regulatory Bodies
12.17.1 Therapeutic Success in European Clinical Trials
12.17.2 Primary End Points in FDA Guidelines
12.18 Reduction in Hospital Infection Rates – Reducing Demand for Antibacterial Drugs
12.19 Enticing Antibacterial Drug Discovery – Push and Pull Incentives
12.19.1 GAIN act: Post-Development Pull Incentives in the US
12.19.2 ADAPT – Building on the GAIN act
12.19.3 EMA Update Guideline – Streamlining Clinical Trials in the EU
12.19.4 Push Incentives for Antibacterial Drug Discovery with Public Funding
12.19.5 IMI: Public-Private Collaboration with GSK and AstraZeneca
12.19.6 Public Finance Pumping Money into Antibacterial Development

13. Research Interviews from Our Survey
13.1 Dr. Holger Zimmermann, Chief Executive Officer (CEO) of AiCuris Anti-infective Cures GmbH
13.1.1 AiCuris Anti-infective Cures GmbH
13.1.2 Introduction
13.1.3 Antibacterial Drugs Market – What Dynamic Have You Observed?
13.1.4 Antibacterial Drugs Market – Drivers and Restraints
13.1.5 What Technological Advances Will Benefit the Antibacterial Drugs Market?
13.1.6 The Burden of Carbapenem-resistant organisms in Germany
13.1.7 AiCuris – Present Development Status of AIC499
13.2 Dr Bruce R. Donald (Duke University), Dr Amy C. Anderson (University of Connecticut), and Mr. Pablo Gainza-Cirauqui (Duke University)
13.2.1 OSPREY
13.2.2 OSPREY – Specializes in Accurate Negative Design
13.2.3 Technical Challenges in Predicting Mutations
13.2.4 Success Rate – Top Four Predictions Confirmed in vitro
13.2.5 OSPREY Could Potentially Predict Resistance Mutations to Biologics (mAbs)
13.2.6 Further Work: Optimize Antibody for Highest in vivo Efficacy
13.2.7 Anticipate Mutations – Redesign Drugs to Maximize Effective Lifespan

14. Antibacterial Drugs Market to 2026: Conclusions
14.1 Three Blockbuster Antibacterials in 2015, Leading Brands
14.2 The Leading Branded Antibacterial Drugs in 2026
14.3 Signs of Life in the Antibacterial R&D Pipeline
14.4 Stemming the Tide of Antibacterial Drug Resistance
14.5 The Changing Face of Antibacterial Clinical Development

Appendices
Some Associated Visiongain Reports
Visiongain Report Sales Order Form
About Visiongain
Visiongain Report Evaluation Form


【レポート販売概要】

■ タイトル:抗菌薬の世界市場:セファロスポリン、ペニシリン、フルオロキノロン、マクロライド系薬、カルバペネム系薬
■ 英文:Antibacterial Drugs: World Industry and Market Prospects 2016-2026
■ 発行日:2016年3月
■ 調査会社:visiongain
■ 商品コード:VGAIN6041536
■ 調査対象地域:グローバル
  • エトキシレートの世界市場:アルコール、脂肪族アミン、メチルエステル、グリセリド・エトキシレート
    The market for ethoxylates is estimated to grow on account of the increasing surfactants, and household & personal care market. The shift in lifestyles of consumers in major developing economies is also a major driving factor of the ethoxylates market. The factors restraining the market growth are low demand in developed nations and environmental regulations regarding the use of ethoxylates. The e …
  • チタン鉱採鉱の世界市場:チタン鉄鉱、ルチル
    About Titanium Ore Mining Titanium is a transition metal with a melting point of 3,032°F. The metal is abundant in the Earth's crust and has excellent corrosion resistant property. Ilmenite and rutile are the two major titanium ores. Titanium has a high strength-to-weight ratio and excellent temperature resistance properties. The aerospace and aviation industry is the prime end-user for titanium. …
  • 救急医療情報システム(EDIS)の世界市場
    This report segment the global EDIS market by application, end user, software type, delivery mode, and region. The application segments included in this report are clinical documentation; E-prescribing; order entry (CPOE), patient tracking, resource tracking and management; and other applications. The end-user segments of this market are small hospitals (1–200 beds), mid-size hospitals (201–500 be …
  • 歯科用3Dプリンティング機器の世界市場2019-2023
    About this market Strategic collaborations and M&A to drive market growth. The global dental 3D printing devices market is observing a trend of strategic collaborations and M&A. Vendors are increasingly collaborating with other companies and research institutions to develop new technologies, enhance their product offerings, and expand their distribution networks. Technavio’s analysts have predicte …
  • グローバルおやつ(Snacking)市場動向
    Summary Snacking – understanding existing trends, capitalizing on new trends and looking to counteract inhibitors in the market is a detailed insight report highlighting the most important trends and untapped opportunities in snacking markets. The increase of fragmented meal times and the need for on-the-go products in both developed and emerging economies are directly influencing consumer product …
  • 家庭用殺虫剤の世界市場:スプレー、気化器、蚊取り線香、餌、その他
    Global Household Insecticide Market: About this market An insecticide is a substance that is used to kill insects. Technavio’s household insecticide market analysis considers sales from segments including sprays, vaporizers, mosquito coils, baits, and others. Our analysis also considers the sales of household insecticide in APAC, Europe, North America, South America, and MEA. In 2018, the sprays s …
  • 水産養殖向け水処理技術の世界市場2016-2020
    About Water Treatment Market for Aquaculture Aquaculture aims to ensure viable production of seafood for commercial use; it uses a host of techniques and technologies to raise aquatic plant and animal species. Apart from producing seafood, it also helps to restore the aquatic population and makes the habitat conducive for marine organisms. It enhances the proliferation of wild fish, which live und …
  • 世界の4WD(四輪駆動)及びADW(全輪駆動)小型車市場(2008-2028)
    This latest just-auto report edition offers a global review of the OE 4WD and AWD sector, its suppliers, top markets, technologies and market forecasts. This global market study offers: Automotive OE 4WD and AWD market size estimates Latest technologies and trends Market share data tables Exclusive interviews with major companies Profiles of the major players including their strategies and prospec …
  • 2014年戦略提言:スペインの腸疾患診断検査市場
    About This ReportThis new 322-page report from Venture Planning Group presents detailed analysis of the Spanish Enteric Diseases market, including sales forecasts and supplier shares for Campylobacter, Cryptosporidium, E. Coli, Enterovirus, Rhinovirus, Rotavirus, Salmonella, Shigella, Vibrio and Yersinia.  The report provides test volume and sales projections for Hospitals and Commercial/Priv …
  • 世界の高度計システム及びピトー管(航空用・防衛用)市場(2014 – 2020)
    Report Description This report presents the complete analysis and information about the global altimeter systems and pitot tube market for the aerospace and defense industry across the time span of six years (2014-2020). A complete analysis of the global altimeter systems and pitot tube market for North America, Latin America, Europe, Asia-Pacific, the Middle East, and Rest of the World has been p …
  • 代謝性疾患治療薬の世界市場:投与経路別、疾患別(糖尿病、リソソーム障害)、治療種類別、地域別、セグメント予測
    The global metabolic disorder therapeutics market size is expected to reach USD 88.93 billion by 2025, according to a new report by Grand View Research, Inc. The market is anticipated to witness a CAGR of 7.56% during the estimated period. Rising incidences of diabetes, obesity, and hypercholesterolemia are expected to drive the market growth. It is estimated that by 2040, about 1 person in 11 peo …
  • 農業用ハーベスタの世界市場:コンバインハーベスタ、フォーレージハーベスタ
    About the Agricultural Harvester Market The market is driven by a number of factors, with the shrinking labor force being one of the most important triggers. As a result of the shrinking labor force, farmers have to bear the significant business loss, especially at the time of harvesting and are investing in harvesters, which allow for highly efficient farming. An increase in government support an …
  • グローバルにおけるデジタルビデオレコーダー市場(2014-2018)
    About Digital Video Recorders A digital video recorder is a consumer electronics device that records video in a digital format to a disk drive, USB flash drive, SD memory card, SSD or other local or networked mass storage device. It is an advanced form of personal video recorder that uses a hard drive instead of video tapes. It is used to record, save, and play back television programs. TechNavio' …
  • Siemens Healthcare:市場シェア分析
    Siemens Healthcare Market Share Analysis Summary GlobalData’s new report, “Siemens Healthcare Market Share Analysis” provides in-depth information on Siemens Healthcare’s market position in the different medical equipment markets it operates in. The report provides Siemens Healthcare market share information in eighteen key market categories – Hearing Aid Devices, Clinical Chemistry, Genetic Testi …
  • 流体管理デバイスの世界市場
    ABSTRACTAbout Fluid Management Devices A fluid management device is primarily used to balance body fluid to prevent complications associated with the improper flow of fluids, undesired fluid levels, fluids with different temperature, and improper disposal of fluids. It is designed to manage the patient's fluid levels internally and externally through a safe, effective, and accurate process. The fl …
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。